PMID- 36583006
OWN - NLM
STAT- MEDLINE
DCOM- 20230102
LR  - 20230127
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - The effect of metformin usage on survival outcomes for hepatocellular carcinoma 
      patients with type 2 diabetes mellitus after curative therapy.
PG  - 1060768
LID - 10.3389/fendo.2022.1060768 [doi]
LID - 1060768
AB  - OBJECTIVE: Metformin has attracted more attention from researchers for its newly 
      discovered antitumor effects. A meta-analysis was performed to reveal the 
      efficacy of metformin on overall survival (OS) and recurrence-free survival (RFS) 
      for HCC patients with type 2 diabetes mellitus (T2DM) after curative treatment. 
      METHODS: Databases including PubMed, the Cochrane Library, Web of Science, CNKI, 
      Wangfang, and Weipu Database up until 31 May 2022 were searched for relevant 
      studies. STATA 13.0 was used to perform the meta-analysis. RESULTS: A total of 
      six studies involving 5,936 patients were included in our study. The results from 
      the current study revealed that metformin usage can significantly prolong the 
      3-year [odds ratio (OR) = 1.50, 95% confidence interval (CI): 1.22-1.83, p = 
      0.000] and 5-year (OR = 1.88, 95% CI: 1.47-2.41, p = 0.000) OS and decrease the 
      1-year (OR = 1.31, 95% CI: 1.08-1.59, p = 0.007), 3-year (OR = 1.88, 95% CI: 
      1.48-2.37, p = 0.000), and 5-year (OR = 1.83, 95% CI: 1.40-2.40, p = 0.000) 
      recurrence rates. CONCLUSION: Metformin treatment significantly prolongs the OS 
      and decreases the recurrence rate for HCC patients with T2DM after curative HCC 
      therapy.
CI  - Copyright (c) 2022 Yuan, Ma, Wang and Hao.
FAU - Yuan, Bo
AU  - Yuan B
AD  - Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, 
      China.
FAU - Ma, Jichun
AU  - Ma J
AD  - First College of Clinical Medicine, Lanzhou University, Lanzhou, China.
FAU - Wang, Jing
AU  - Wang J
AD  - Cadre Ward Endocrinology Department, Gansu Provincial Hospital, Lanzhou, China.
FAU - Hao, Jinyong
AU  - Hao J
AD  - Department of Gastroenterology, Lanzhou University Second Hospital, Lanzhou, 
      China.
LA  - eng
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20221213
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/complications/drug therapy
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - *Metformin/therapeutic use
MH  - *Liver Neoplasms/drug therapy
MH  - Odds Ratio
PMC - PMC9792596
OTO - NOTNLM
OT  - diabetes mellitus
OT  - hepatocellular carcinoma
OT  - metformin
OT  - overall survival
OT  - recurrence-free survival
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/31 06:00
MHDA- 2023/01/03 06:00
PMCR- 2022/01/01
CRDT- 2022/12/30 02:35
PHST- 2022/10/03 00:00 [received]
PHST- 2022/11/28 00:00 [accepted]
PHST- 2022/12/30 02:35 [entrez]
PHST- 2022/12/31 06:00 [pubmed]
PHST- 2023/01/03 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.1060768 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Dec 13;13:1060768. doi: 
      10.3389/fendo.2022.1060768. eCollection 2022.